e-Lung Computed Tomography Biomarker Stratifies Patients at Risk of Idiopathic Pulmonary Fibrosis Progression in a 52-Week Clinical Trial

Am J Respir Crit Care Med. 2024 May 1;209(9):1168-1169. doi: 10.1164/rccm.202312-2274LE.

Anand Devaraj^{1

2}, Finja Ottink³, Christian Rennison-Jones³, François-Xavier Blé⁴, Olivier Joly³, Adnan Azim^{4

5}, Stephen Gerry⁶, George Harston^{3

7}, Kristoffer Ostridge^{5

8}, Peter M George^{1

2}

¹ Royal Brompton Hospital, London, United Kingdom.
² National Heart and Lung Institute, Imperial College London, London, United Kingdom.
³ Brainomix, Oxford, United Kingdom.
⁴ Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
⁵ Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
⁶ Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom.
⁷ Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom; and.
⁸ Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

No abstract available

Publication types